The Relationship between Frequently Used Glucose-Lowering Agents and Gut Microbiota in Type 2 Diabetes Mellitus

Metabolic diseases, especially diabetes mellitus, have become global health issues. The etiology of diabetes mellitus can be attributed to genetic and/or environmental factors. Current evidence suggests the association of gut microbiota with metabolic diseases. However, the effects of glucose-lowering agents on gut microbiota are poorly understood. Several studies revealed that these agents affect the composition and diversity of gut microbiota and consequently improve glucose metabolism and energy balance. Possible underlying mechanisms include affecting gene expression, lowering levels of inflammatory cytokines, and regulating the production of short-chain fatty acids. In addition, gut microbiota may alleviate adverse effects caused by glucose-lowering agents, and this can be especially beneficial in diabetic patients who experience severe gastrointestinal side effects and have to discontinue these agents. In conclusion, gut microbiota may provide a novel viewpoint for the treatment of patients with diabetes mellitus.

• Publication year

  2018

• Venue

  Journal of Diabetes Research

• Publication date

  2018-05-07

• Fields of study

  Biology, Medicine, Environmental Science

• Identifiers
  DOI 10.1155/2018/1890978PMID 29854817PMCID 5964532
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial

  2017cited by this paper
• Vildagliptin increases butyrate-producing bacteria in the gut of diabetic rats

  2017cited by this paper
• A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism.

  2017cited by this paper
• Involvement of gut microbiota in association between GLP-1/GLP-1 receptor expression and gastrointestinal motility.

  2017cited by this paper
• A Specific Gut Microbiota Dysbiosis of Type 2 Diabetic Mice Induces GLP-1 Resistance through an Enteric NO-Dependent and Gut-Brain Axis Mechanism.

  2017cited by this paper
• Metformin alters the gut microbiome of individuals with treatment-naive type 2 diabetes, contributing to the therapeutic effects of the drug

  2017influential reference
• DBZ is a putative PPARγ agonist that prevents high fat diet-induced obesity, insulin resistance and gut dysbiosis.

  2017cited by this paper
• Effects of Acarbose on the Gut Microbiota of Prediabetic Patients: A Randomized, Double-blind, Controlled Crossover Trial

  2017influential reference
• Analyses of gut microbiota and plasma bile acids enable stratification of patients for antidiabetic treatment

  2017cited by this paper
• Sodium butyrate reduces insulin-resistance, fat accumulation and dyslipidemia in type-2 diabetic rat: A comparative study with metformin.

  2016cited by this paper
• Revised Estimates for the Number of Human and Bacteria Cells in the Body

  2016cited by this paper
• Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid–Producing Microbiota in the Gut

  2016cited by this paper
• Microflora Disturbance during Progression of Glucose Intolerance and Effect of Sitagliptin: An Animal Study

  2016cited by this paper
• Impact of the gut microbiota on inflammation, obesity, and metabolic disease

  2016cited by this paper
• Metformin and the gastrointestinal tract

  2016influential reference
• Insulin Sensitivity-Enhancing Activity of Phlorizin Is Associated with Lipopolysaccharide Decrease and Gut Microbiota Changes in Obese and Type 2 Diabetes (db/db) Mice.

  2016cited by this paper
• Acetate mediates a microbiome-brain-β cell axis promoting metabolic syndrome

  2016cited by this paper
• Antidiabetic (type 2) effects of Lactobacillus G15 and Q14 in rats through regulation of intestinal permeability and microbiota.

  2016cited by this paper
• Intestinal SGLT1 in metabolic health and disease.

  2016cited by this paper
• Impact of gut microbiota on diabetes mellitus.

  2016cited by this paper
• A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice

  2016cited by this paper
• Cardiovascular risk associated with acarbose versus metformin as the first-line treatment in patients with type 2 diabetes: a nationwide cohort study.

  2015cited by this paper
• Cathelicidin Antimicrobial Peptide: A Novel Regulator of Islet Function, Islet Regeneration, and Selected Gut Bacteria

  2015cited by this paper
• Metformin activates a duodenal Ampk–dependent pathway to lower hepatic glucose production in rats

  2015cited by this paper
• Acarbose treatment affects the serum levels of inflammatory cytokines and the gut content of bifidobacteria in Chinese patients with type 2 diabetes mellitus

  2015influential reference
• Modulation of gut microbiota by berberine and metformin during the treatment of high-fat diet-induced obesity in rats

  2015cited by this paper
• New mechanisms of metformin action: Focusing on mitochondria and the gut

  2015cited by this paper
• Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review

  2015cited by this paper
• The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies

  2015cited by this paper
• Obesity, inflammation, and the gut microbiota.

  2015cited by this paper
• Addition of a Gastrointestinal Microbiome Modulator to Metformin Improves Metformin Tolerance and Fasting Glucose Levels

  2015cited by this paper
• Disentangling the effects of type 2 diabetes and metformin on the human gut microbiota

  2015cited by this paper
• Disentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota

  2015influential reference
• Lactobacillus strains isolated from infant faeces possess potent inhibitory activity against intestinal alpha- and beta-glucosidases suggesting anti-diabetic potential

  2014cited by this paper
• Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial.

  2014cited by this paper
• Gut Dysbiosis and Detection of “Live Gut Bacteria” in Blood of Japanese Patients With Type 2 Diabetes

  2014cited by this paper
• Gut microbiota and GLP-1

  2014cited by this paper
• The role of short-chain fatty acids in health and disease.

  2014cited by this paper
• Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus

  2014cited by this paper
• Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study

  2014cited by this paper
• Acarbose Treatment and the Risk of Cardiovascular Disease in Type 2 Diabetic Patients: A Nationwide Seven-Year Follow-Up Study

  2014cited by this paper
• On the potential of acarbose to reduce cardiovascular disease

  2014cited by this paper
• Insights Into the Role of the Microbiome in Obesity and Type 2 Diabetes

  2014cited by this paper
• Supplemental Figure 1

  2014cited by this paper
• Impact of diet and individual variation on intestinal microbiota composition and fermentation products in obese men

  2014cited by this paper
• A novel cobiotic containing a prebiotic and an antioxidant augments the glucose control and gastrointestinal tolerability of metformin: a case report.

  2014cited by this paper
• Effect of Metformin on Metabolic Improvement and Gut Microbiota

  2014cited by this paper
• LX4211 Increases Serum Glucagon-Like Peptide 1 and Peptide YY Levels by Reducing Sodium/Glucose Cotransporter 1 (SGLT1)–Mediated Absorption of Intestinal Glucose

  2013cited by this paper
• Single phosphorylation sites in Acc1 and Acc2 regulate lipid homeostasis and the insulin–sensitizing effects of metformin

  2013cited by this paper
• Richness of human gut microbiome correlates with metabolic markers

  2013cited by this paper
• Gut metagenome in European women with normal, impaired and diabetic glucose control

  2013cited by this paper
• Erratum to: Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

  2013cited by this paper
• Alterations in fecal Lactobacillus and Bifidobacterium species in type 2 diabetic patients in Southern China population

  2013cited by this paper
• Conserved Shifts in the Gut Microbiota Due to Gastric Bypass Reduce Host Weight and Adiposity

  2013cited by this paper
• An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice

  2013cited by this paper
• Transglucosidase improves the gut microbiota profile of type 2 diabetes mellitus patients: a randomized double-blind, placebo-controlled study

  2013cited by this paper
• The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism

  2013cited by this paper
• The Primary Research on the Gut Microbes in KKAy Mice

  2013cited by this paper
• GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes.

  2013cited by this paper
• Metformin Retards Aging in C. elegans by Altering Microbial Folate and Methionine Metabolism

  2013cited by this paper
• Biguanides suppress hepatic glucagon signaling by decreasing production of cyclic AMP

  2012cited by this paper
• Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach

  2012cited by this paper
• Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2

  2012cited by this paper
• A metagenome-wide association study of gut microbiota in type 2 diabetes

  2012cited by this paper
• Impact of Metformin-Induced Gastrointestinal Symptoms on Quality of Life and Adherence in Patients with Type 2 Diabetes

  2010cited by this paper
• Are the effects of α‐glucosidase inhibitors on cardiovascular events related to elevated levels of hydrogen gas in the gastrointestinal tract?

  2009cited by this paper
• Harrison's principles of internal medicine, McGraw Hill New York (1998) pp.2570.

  2008influential reference
• Metformin and the intestine

  2008cited by this paper
• Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41

  2008cited by this paper
• Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia

  2007cited by this paper
• Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin

  2004cited by this paper
• Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin

  2004cited by this paper
• Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.

  2004cited by this paper
• Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

  2003cited by this paper
• Acarbose raises serum butyrate in human subjects withimpaired glucose tolerance

  2000cited by this paper
• Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria

  1999cited by this paper
• Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE study group. European Diabetes Epidemiology Group. Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe.

  1999cited by this paper
• Acarbose enhances human colonic butyrate production.

  1997cited by this paper
• Harrison's Principles of Internal Medicine

  1988cited by this paper
• Lack of effect of intravenous metformin on plasma concentrations of glucose, insulin, C-peptide, glucagon and growth hormone in non-diabetic subjects.

  1984cited by this paper

• In vitro digestion and fermentation of ginseng pectic polysaccharide GPS-1 and attenuation of its product on oleic acid-induced oxidative stress in HepG2 cells.

  2026cites this paper
• Sodium Butyrate Supplementation in Whole Milk Modulates the Gastrointestinal Microbiota Without Altering the Resistome and Virulome in Preweaned Calves

  2025cites this paper
• The gut and lung microbiome across the TB disease spectrum

  2025cites this paper
• Baseline glucagon impacts glucose-lowering effects of acarbose but not metformin: A sub-analysis of MARCH study.

  2025cites this paper
• Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: A review

  2024cites this paper
• Preparation, bioactivities, and food industry applications of tuber and tuberous roots peptides: A review.

  2024cites this paper
• De-starched Panax ginseng polysaccharide: Preparation, in vitro digestion, fermentation properties and the activating effect of the resultant products on RAW264.7 cells.

  2024cites this paper
• Fermented Ananas comosus and Carica papaya harbor putative probiotic Limosilactobacillus fermentum and Lacticaseibacillus paracasei strains with inhibitory activity against α-glucosidase and α-amylase

  2024cites this paper
• Berberine Treats Type 2 Diabetes by Regulating Gutmicrobiota

  2024cites this paper
• Development of Microrobot with Optical Magnetic Dual Control for Regulation of Gut Microbiota

  2023cites this paper
• Effects of Mulberry Leaf Fu Tea on the Intestines and Intestinal Flora of Goto-Kakizaki Type 2 Diabetic Rats

  2023cites this paper
• Are There Differences in Gut Microbiome in Patients with Type 2 Diabetes Treated by Metformin or Metformin and Insulin?

  2022cites this paper
• Design, synthesis, spectroscopic characterizations, antidiabetic, in silico and kinetic evaluation of novel curcumin-fused aldohexoses.

  2022cites this paper
• Are There Differences in Gut Microbiome in Patients with Type 2 Diabetes Treated by Metformin or Metformin and Insulin? Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy

  2022cites this paper
• The Effect of Prebiotics and Oral Anti-Diabetic Agents on Gut Microbiome in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis of Randomised Controlled Trials

  2022influential citation
• Helicobacter pylori infection-induced changes in the intestinal microbiota of 14-year-old or 15-year-old Japanese adolescents: a cross-sectional study

  2021cites this paper
• Unconjugated p-cresol activates macrophage macropinocytosis leading to increased LDL uptake

  2021cites this paper
• Dairy product intake modifies gut microbiota composition among hyperinsulinemic individuals

  2020cites this paper
• Sargassum fusiforme Polysaccharides Prevent High-Fat Diet-Induced Early Fasting Hypoglycemia and Regulate the Gut Microbiota Composition

  2020cites this paper
• Serum miRNA Profile in Diabetic Patients With Ischemic Heart Disease as a Promising Non-Invasive Biomarker

  2020cites this paper
• Gut Microbiota and the Development of Type 2 Diabetes

  2020cites this paper
• Dietary pattern, colonic microbiota and immunometabolism interaction: new frontiers for diabetes mellitus and related disorders

  2020cites this paper
• Identification of key genes involved in type 2 diabetic islet dysfunction: a bioinformatics study

  2019cites this paper
• The role of chronic kidney disease-associated dysbiosis in cardiovascular disease

  2019cites this paper
• The new views on the state of the gut microbiota in obesity and diabetes mellitus type 2

  2019cites this paper
• Efficacy of UB0316, a multi-strain probiotic formulation in patients with type 2 diabetes mellitus: A double blind, randomized, placebo controlled study

  2019cites this paper
• Metformin and Its Benefits in Improving Gut Microbiota Disturbances in Diabetes Patients

  2019cites this paper
• Fecal microbiota analysis of polycystic kidney disease patients according to renal function: A pilot study

  2018cites this paper
• Vildagliptin: ten years in the service for type 2 diabetes mellitus patients. The journey of discovery, innovation and success in clinical practice

  2018cites this paper